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BACKGROUND: Biochemical markers that accurately re-
flect the severity and progression of disease in patients
with Fabry disease and their response to treatment are
urgently needed. Globotriaosylsphingosine, also called
lysoglobotriaosylceramide (lysoGb3), is a promising
candidate biomarker.
METHODS: We synthesized lysoGb3 and isotope-labeled
[5,6,7,8,9] 13C5-lysoGb3 (internal standard). After ad-
dition of the internal standard to 25 L plasma or 400
L urine from patients with Fabry disease and healthy
controls, samples were extracted with organic solvents
and the lysoGb3 concentration was quantified by UPLC-
ESI-MS/MS (ultraperformance liquid chromatography–
electrospray ionization–tandem mass spectrometry).
Calibration curves were constructed with control
plasma and urine supplemented with lysoGb3. In ad-
dition to lysoGb3, lyso-ene-Gb3was quantified. Quan-
tification was achieved by multiple reaction monitor-
ing of the transitions m/z 786.4  282.3 [MH] for
lysoGb3, m/z 791.4  287.3 [MH] for [5,6,7,8,9]
13C5-lysoGb3, and 784.4  280.3 [MH]
 for
lyso-ene-Gb3.
RESULTS: The mean (SD) plasma lysoGb3 concentra-
tion from 10 classically affected Fabry hemizygotes was
94.4 (25.8) pmol/mL (range 52.7–136.8 pmol/mL),
from 10 classically affected Fabry heterozygotes 9.6
(5.8) pmol/mL (range 4.1–23.5 pmol/mL), and from
20 healthy controls 0.4 (0.1) pmol/mL (range 0.3–0.5
pmol/mL). Lyso-ene-Gb3 concentrations were 10%–
25% of total lysoGb3. The urine concentration of
lysoGb3 was 40–480 times lower than in correspond-
ing plasma samples. Lyso-ene-Gb3 concentrations in
urine were comparable or even higher than the corre-
sponding lysoGb3 concentrations.
CONCLUSIONS: This assay for the quantification of
lysoGb3 and lyso-ene-Gb3 in human plasma and urine
samples will be an important tool in the diagnosis of
Fabry disease and for monitoring the effect of enzyme
replacement therapy in patients with Fabry disease.
© 2012 American Association for Clinical Chemistry
Fabry disease is an X-linked hereditary disorder
caused by a deficiency of the lysosomal enzyme
-galactosidase A. The defect results in the accumula-
tion of globotriaosylceramide (Gb3),4 galabiaosylcer-
amide, and blood group B glycolipids (1 ). Clinically,
patients manifest angiokeratoma, anhidrosis, and
acroparesthesias, and in later stages cardiomyopathy,
cerebrovascular disease, and renal insufficiency. Both
men and women are affected by the disease, although
the clinical manifestations are generally less severe in
heterozygote women (1 ). Two different recombinant
-galactosidase A preparations, algalsidase alfa (Repla-
gal, Shire HGT) and agalsidase  (Fabrazyme, Gen-
zyme Corp), are approved for the treatment of Fabry
disease. The enzyme therapies involve 2 weekly intra-
venous infusions of an enzyme preparation (2 ). Labo-
ratory monitoring of disease progression in Fabry pa-
tients has been based on measurement of plasma and
urinary Gb3 (3 ). However, the concentration of this
lipid is not abnormal in the plasma of most female
Fabry heterozygotes, even when symptomatic (4 ). We
previously reported on a much more prominent lipid
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abnormality in plasma of Fabry patients (5 ). The
deacylated form of globotriaosylceramide, globotriao-
sylsphingosine (lysoGb3), is increased approximately
100-fold in the plasma of symptomatic Fabry hem-
izygotes and it is also increased in the plasma of
symptomatic Fabry females (5 ), a finding that has
been confirmed by other studies (6 –9 ). Quantifica-
tion of plasma lysoGb3 is of value for confirmation of
the diagnosis of Fabry disease, especially in the case of
female patients. Moreover, monitoring of the changes
in plasma lysoGb3 concentrations in Fabry patients
following enzyme therapy renders insight into the bio-
chemical efficacy of the costly therapeutic intervention.
We previously employed a procedure for quantifying
lysoGb3 that was based on derivatization of the amine
in the lysoglycolipid with orthophthaldialdehyde
(OPA), followed byHPLC separation and fluorescence
detection (5, 10, 11). This method is able to quantify
the increased concentrations of lysoGb3 in plasma of
classically affected male Fabry patients. However, with
a detection limit of about 3 nmol/L, the method is not
analytically sensitive enough to accurately quantify
lipid concentrations in plasma obtained from healthy
individuals, nor in plasma samples from a large pro-
portion of female heterozygous Fabry patients. More-
over, the original procedure is hampered by the fact
that plasma samples may contain other OPA-reactive
compounds that can interfere with detection of lysoGb3.
This procedure thus requires multiple extractions and
a mild alkaline hydrolysis step to obtain sufficiently
pure preparations of lysoGb3 to allow reliable detec-
tion by the HPLC-based procedure (10, 11).
Here we present a new method for the quantifi-
cation of lysoGb3 based on ultraperformance liquid
chromatography– electrospray ionization–tandem
mass spectrometry (UPLC-ESI-MS/MS) and the use of
[5,6,7,8,9] 13C5-labeled lysoGb3 as the internal stan-
dard, which was synthesized for this particular pur-
pose. In addition, we quantify a compound closely re-
lated to lysoGb3, lyso-ene-Gb3.
Material andMethods
PATIENT SAMPLES
Plasma and urine samples were obtained from men
and women affected by classical Fabry disease (1 ) re-
ferred to the Lysosomal Outpatient Clinic of the Aca-
demic Medical Center in Amsterdam. The diagnosis
had been confirmed by demonstrating a deficiency of
-galactosidase A in leukocytes and a mutation in the
galactosidase, alpha (GLA) gene in male patients. Clas-
sically affected female patients were from families with
classically affected males and their diagnosis had been
confirmed bymutation analysis of theGLA gene. Con-
trol samples were obtained from age-matched healthy
volunteers (21–60 years old). Informed consent was
obtained according to the Declaration of Helsinki.
Plasma was obtained from 5mL EDTA-anticoagulated
blood after centrifugation at 1750g for 10 min and
stored at 20 °C until use. Urine samples from 24-h
collections or early morning voids were stored at
20 °C until use. On thawing the urine samples were
vigorously mixed to ensure that the sample was homo-
geneous. LysoGb3 is stable in plasma and urine for at
least 5 days at room temperature and at 4 °C and for at
least 1 year at 20 °C (see Fig. 1 in the Data Supple-
ment that accompanies the online version of this article
at http://www.clinchem.org/content/vol59/issue3).
SYNTHESIS OF UNLABELED AND [5,6,7,8,9] 13C5-LABELED LysoGb3
Nonlabeled lysoGb3 was synthesized as previously
described (12). The synthesis of [5,6,7,8,9] 13C5-
labeled lysoGb3 was accomplished as depicted in the
scheme in the online Supplemental Data file. Key to the
synthetic scheme was the preparation of [5,6,7,8,9]-
13C5-erythro-sphingosine 10, which was accomplished
as follows (for full experimental and analytical details
see the online Supplemental Data). The stable isotopes
were introduced in 3 consecutive additions of 13C-
labeled reagents starting from 1-bromononane 1. Dis-
placement of the bromine with 13C1-potassium cya-
nide yielded 1-13C1-decanitrile 2. Partial reduction of
the nitrile gave 1-13C1-decanal 3, which was elongated
using 13C2-labeled Horner-Wadsworth-Emmons re-
agent 4. Reduction of the double bond in the resulting
13C3-Weinreb amide 5 was followed by partial reduc-
tion to the aldehyde and a second condensation with
HWE reagent 4 to give 13C5-Weinreb amide 6. Reduc-
tion of the double bond and partial reduction of the
Weinreb amide to the aldehyde provided an interme-
diate 13C5-tetradecanal, which was homologated with
methyltriphenylphosphonium bromide to give 13C5-
pentadec-1-ene 7. The 13C5-labeled sphingosine 9 was
then prepared using a cross-metathesis methodology
in which the known chiral allylic alcohol 8 served as the
second olefin reaction partner, next to 13C5-olefin 7.
Benzoylation of the secondary alcohol in 9was fol-
lowed by selective removal of the isopropylidene group
to give primary alcohol 10. In the final stages of the
synthesis, compound 10 was condensed with protected
globotriaosyl donor 11. The resulting 13C5-labeled
lysoGb3 construct was globally deprotected in a 4-step
sequence and purified to homogeneity by reverse-
phase HPLC.
In addition to the syntheticmaterial, 1-mg batches
of nonlabeled lysoGb3 derived from natural sources
were obtained from Sigma (product G9534, lot num-
bers 071K2130 and 078K1124). LC-MS–grade metha-
nol, water and formic acid and HPLC-grade CHCl3
were purchased from Biosolve. Ammonium formate
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(LC-MS grade) was purchased from Sigma-Aldrich
Chemie GmbH.
EXTRACTION OF LysoGb3 FROM PLASMA
LysoGb3 was extracted from plasma by a modification
of the method of Bligh and Dyer (13). Briefly, 50 L
plasma was pipetted in an Eppendorf tube, 25 L in-
ternal standard ([5,6,7,8,9] 13C5-labeled lysoGb3, 0.1
nmol/mL in methanol) was added, and the tube was
stirred briefly. Subsequently, 25LH2O, 300Lmeth-
anol, and 150L chloroformwere added with 1min of
stirring after each addition. The sampleswere left for 30
min at room temperature. After centrifugation for 10
min at 15 700g in a 5415 D Eppendorf centrifuge to
spin down precipitated protein, the supernatants were
transferred to clean Eppendorf tubes and 150 L chlo-
roform and 225LH2Owere added. After stirring, the
tubes were centrifuged for 2 min at 15 700g to separate
the 2 phases. From the upper phase, 400 L was trans-
ferred to a 2-mL clean tube (extract A). The lower
phase was extracted by subsequent addition of 300 L
methanol and 300 L H2O and stirring for 1 min. The
samples were centrifuged for 2 min at15 700g and the
upper phase was removed, pooled with extract A, and
taken to dryness at 35 °C under a nitrogen stream. The
residue was dissolved in 100Lmethanol, stirred for 1
min, and sonicated for 30 s in a bath sonifier. The sam-
ples were centrifuged for 10 min at 15 700g in the Ep-
pendorf centrifuge to precipitate any insoluble mate-
rial. The recovery of lysoGb3 with this method was
98%. The isotope-labeled standard is presently not
available for distribution because of its scarcity.
EXTRACTION OF LysoGb3 FROM URINE
LysoGb3was extracted fromurine by amodification of
the method of Bligh and Dyer (13). LysoGb3 was
nearly quantitatively recovered in the upper phase. The
upper phase containing the lysoGb3 was taken to dry-
ness, dissolved in n-butanol, and extracted with water
(11). LysoGb3 was nearly quantitatively recovered in
the butanol phase. The overall recovery of lysoGb3
with this method was80%.
Briefly, to 400 L of urine in an Eppendorf tube,
40 L of internal standard ([5,6,7,8,9] 13C5-labeled
lysoGb3, 10 pmol/mL) was added and stirred briefly.
Then, 960Lmethanol and 500L CHCl3 were added
with brief stirring. The samples were left at ambient
temperature for 30 min, stirred occasionally, and cen-
trifuged for 10 min at 15 700g in a 5415 D Eppendorf
centrifuge to spin down precipitated protein. The su-
pernatant was transferred to a glass tube, and 500 L
H2O (Milli-Q) and 500 L CHCl3 were added with
stirring. The tubes were centrifuged for 5 min at 2500g
in a 5810 R Eppendorf centrifuge to separate the
phases. The upper methanol/water phase was trans-
ferred to a 2-mLEppendorf tube.No attemptwasmade
to completely recover the upper phase, because care
was taken not to disturb the interphase, which may
contain protein in urines fromFabry patients with pro-
teinuria. The sample was dried under a gentle streamof
nitrogen at 35 °C, and the residue was dissolved in 800
L butanol saturated with water. Then 800 L H2O
saturated with butanol was added and the sample was
stirred briefly and centrifuged for 5 min in the Ep-
pendorf centrifuge at 15 700g. The upper (butanol)
phase was transferred to a 1.5-mL polypropylene
tube and the sample was dried under a gentle stream
of nitrogen at 35 °C. No attempt was made to com-
pletely recover the upper phase, because care was
taken not to disturb the interphase. Theoretically the
combined extraction efficiency was 90%. Because
the upper phases were not completely removed the
actual recovery was lower than the theoretical recov-
ery, namely 80%. The presence of the isotope-
labeled internal standard corrected for all losses dur-
ing sample cleanup. The residue was dissolved in 100
L methanol. The samples were sonicated for 30 s in
a bath sonifier and centrifuged for 5 min in the Ep-
pendorf centrifuge at 15 700g.
INSTRUMENTATION
A Waters AcquityTM TQD instrument was used in all
experiments. The instrument consisted of a UPLC sys-
tem combined with a tandem quadrupole mass spec-
trometer as mass analyzer. Data were analyzed with
Masslynx Software (Waters).
OPTIMIZATION OF UPLC CONDITIONS
Analytes were separated on an Acquity BEH C18
reversed-phase column (2.1 50 mm, particle size 1.7
m) (Waters) by using the following eluents: eluent A
was 37% methanol, 0.5% formic acid in UPLC grade
water containing 1 mmol/L ammonium formate; elu-
ent B was 0.5% formic acid in methanol containing
1 mmol/L ammonium formate. Amobile-phase gradi-
ent was used during a 5.50-min run: 0.00 min, 0% B;
2.50 min, 100% B; 4.00 min, 100% B; 5.00 min, 0% B;
5.50 min, 0% B. The flow rate was 0.25 mL/min. The
eluent was diverted towaste between 0.00 and 2.30min
to keep the source free of contaminants; data were col-
lected between 2.30 and 4.05 min, and after 4.05 min
the eluent was again diverted to waste.
OPTIMAL CONDITIONS FOR LysoGb3 DETECTION BY MS/MS
Standard solutions of lysoGb3, [5,6,7,8,9] 13C5-
lysoGb3,and a mixture of both compounds were pre-
pared with concentrations of 1 nmol/mL in 5 mmol/L
ammonium formate/0.5% formic acid in methanol.
The compounds were introduced in the mass spec-
trometer by direct infusion and the optimal tuning
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conditions for both compounds in ES (electrospray
positive) mode were determined, i.e., the signal re-
sponse was optimized as a function of capillary and
cone voltage and of flow and temperature of desolva-
tion gas (nitrogen). Optimal conditions of collision-
induced dissociation for the main transitions m/z
786.4 282.3 [MH] for lysoGb3 and 791.4 287.3
[MH] for 13C5-lysoGb3 were established as a func-
tion of collision energy and collision gas (argon) flow.
The optimal conditions for the detection of lysoGb3 by
UPLC-ESI-MS/MS are shown in Table 1.
DETERMINATION OF LysoGb3 BY HPLC
The measurement of lysoGb3 using derivatization
with orthophthaldialdehyde, HPLC separation with
fluorescence detection was performed as previously
described (11 ).
CHARACTERIZATION OF COMMERCIALLY AVAILABLE STANDARD
Calibration curves from 0–1–2–5 pmol containing 0.5
pmol of [5,6,7,8,9] 13C5-lysoGb3 per injection were
constructed for commercially available lysoGb3 from 2
different lot numbers obtained fromSigmaG9534. The
absolute amounts injected were plotted against the in-
ternal standard ratio. Linear responses were obtained:
y  2.26x, R2  1.000 for lot number 071K2130 and
y  1.00x, R2  0.999 for lot number 078K1124. The
latter standard had been used in previous studies on
lysoGb3 from our laboratory (5, 10, 11). The calibra-
tion curve of the unlabeled standard synthesized in our
laboratory, (y  2.52x, R2  0.999), was highly com-
parablewith the unlabeled Sigma standard (lot number
071K2130). However, a remarkable difference was
found with the slope of the calibration curve of the
commercial standard with lot number 078K1124.
These results were confirmed by HPLC measurements
(data not shown). This finding highlights the need for
certified lipid standards.
Results and Discussion
MASS SPECTROMETRIC ANALYSIS OF UNLABELED AND [5,6,7,8,9]
13C5-LABELED LysoGb3
Mass spectrawere recorded from the newly synthesized
unlabeled and [5,6,7,8,9] 13C5-labeled lysoGb3 in-
jected as a mixture of 1 nmol/mL each. Fig. 1A shows
the mass spectra with the expectedm/z values of 786.4
for the protonated form of unlabeled lysoGb3 andm/z
791.4 for [5,6,7,8,9] 13C5-lysoGb3. In addition to the
protonated forms, the Na-adducts (m/z 808.4 and
813.3, respectively) were detected. This mixture was
used to optimize the conditions for detection by
MS/MS (Table 1). Fig. 1B shows the fragmentation
spectrum of lysoGb3 under optimal conditions of
collision-induced dissociation for the main transi-
tion m/z 786.4  282.3 [MH]. Under these con-
ditions the main positively charged product of
collision-induced dissociation was a fragment ofm/z
282.3[MH] due to the loss of trisaccharide and
H2O from the parent molecule (Fig. 1B, insert). The
optimal conditions for collision-induced dissocia-
tion of [5,6,7,8,9] 13C5-lysoGb3 (main transition
791.4  287.3 [MH]) were identical. This newly
synthesized isotope-labeled internal standard had a
chemical structure identical to lysoGb3 and was thus
ideally suited to compensate for losses during sam-
ple preparation and most importantly for matrix ef-
fects during MS detection.
MATRIX EFFECT: THE BENEFIT OF USING AN ISOTOPE-LABELED
INTERNAL STANDARD
During the initial stages of method development we
compared the absolute signal responses of a calibration
curve of 0–0.01–0.25–0.05–0.1–0.25–0.5 and 1.0
pmol of pure standard lysoGb3 and a calibration curve
of the same amount of standard lysoGb3 spiked in
plasma and extracted by the modified method of
Bligh and Dyer (see above) (14 ). All samples con-
tained 0.25 pmol of [5,6,7,8,9] 13C5-lysoGb3. The
calibration line (area lysoGb3 vs pmol injected) of
the pure standard was y  8532x, R2  0.993. For
Table 1. MS/MS instrument parameters.
Capillary voltage 3.50 kV
Cone voltage 55 V
Source temperature 140 °C
Desolvation temperature 450 °C
Cone gas 50 L/h
Desolvation gas 950 L/h
Collision gas 0.12 mL/min
Collision voltage 40 V
Type Multiple reaction monitoring
Ion mode ES (electrospray positive)
Dwell time 0.100 s
Interchannel delay 0.005 s
Interscan delay 0.005 s
Transitions (lyso-Gb3) m/z 786.4 to m/z 282.3
Transitions [5,6,7,8,9]
13C5 lyso-Gb3)
m/z 791.4 to m/z 287.3
Transitions(lyso-ene-Gb3) m/z 784.4 to m/z 280.3
Fit weight None
Smooth method Mean
Smooth iterations 2
Smooth width 2
Point of origin Force
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spiked plasma extracted by the Bligh and Dyer
method the calibration line was y  15790x, R2 
0.993. The slope of the latter calibration line was 1.85
times that of the pure standard, indicating a signal
enhancement effect of the extraction procedure.
When the absolute amounts injected were plotted
against the ratio of the area of lysoGb3/area of
[5,6,7,8,9] 13C5-labeled internal standard, the fol-
lowing calibration lines were obtained: y  2.941x
for the pure standard and y  2.830x for supple-
Fig. 1. (A), MS-scan of a mixture of lysoGb3 and [5,6,7,8,9] 13C5-lysoGb3 (positive-ion mode); (B) fragmentation
spectrum of lysoGb3.
Conditions optimized for the transition m/z 786.4  282.3 [MH].
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mented plasma. The ratio of the similar slopes was
1.039, demonstrating the value of using the labeled
internal standard for correction of the matrix effect.
CARRYOVER AND REPRODUCIBILITY OF RETENTION TIMES
Carryover between runs was tested by injecting meth-
anol after a run with the highest concentration of pure
standard lysoGb3 (500 pmol/mL) and plasma supple-
mented with lysoGb3 (500 pmol/mL). This corre-
sponded to 2.5 pmol of lysoGb3 per injection. No sig-
nal of lysoGb3 could be detected, demonstrating that
the carryover was essentially zero. The between-run
variability in the retention time of lysoGb3 was 3.15
(0.02) min, CV  0.5%. As expected, identical reten-
tion timeswere found for lysoGb3 and [5,6,7,8,9] 13C5-
labeled lysoGb3.
QUANTIFICATION OF LysoGb3 IN PLASMA
A calibration curve of lysoGb3 in normal control
plasma was constructed. Normal control plasma was
spikedwith lysoGb3 a concentrations from0–2–5–10–
20–50–100–200 pmol/mL, internal standard was
added, and the samples were extracted as described in
the Materials and Methods. The ratio of the area of
lysoGb3/area of [5,6,7,8,9] 13C5-labeled internal stan-
dard was plotted against the concentration of lysoGb3.
A linear response was obtained over the entire concen-
tration range (y 0.025x, R2 0.998). To estimate the
imprecision of the new method, control plasma was
supplemented with lysoGb3 at a high concentration
comparable to concentrations found in hemizygote
Fabry patients as well as a low concentration compara-
ble to concentrations in heterozygotes. The results of
10 consecutive duplicate determinations were calcu-
lated by EP Evaluator® and yielded the following data:
for the high concentration, intraassay, 71.7 (2.5) pmol/
mL, CV 3.5%; interassay, 71.7 (4.6) pmol/mL, CV
6.3%; for the low concentration, intraassay, 17.5 (1.2)
pmol/mL, CV  7%; and interassay 17.5 (0.2) pmol/
mL, CV 1.3%. We compared the data obtained with
the current UPLC-ESI-MS/MS method with those ob-
tained with the HPLC method using the new lysoGb3
standards. Good linearity and a good correlation were
found between the results obtained by both methods
(y 1.13x, R2 0.974).
Next, the lysoGb3 concentrations in plasma sam-
ples of 10 classically affected Fabry hemizygotes, 10
classically affected Fabry heterozygotes, and 20 healthy
individuals (10males and 10 females) were determined
bymass spectrometry (Fig. 2). Although the concentra-
tion of lysoGb3 in plasma samples of male Fabry hem-
izygotes was 100 times higher than in those of healthy
individuals, the wide linear dynamic range and the
great sensitivity allowed accurate quantification in
both groups (Fig. 2). No difference in lysoGb3 concen-
tration was found between male and female control
samples. LysoGb3 was found to be completely stable in
plasma stored at20 °C as judged from more than 20
consecutive lysoGb3 measurements of a reference
plasma sample during a period of at least 2 years (data
not shown). The limit of detection with the mass spec-
trometric method (signal-to-noise ratio of 3) was 0.05
pmol/mL. The signal-to-noise ratio in the case of con-
trol plasma samples was always10 (Fig. 3), allowing
accurate quantification of plasma lysoGb3 even in nor-
mal individuals. These results compare favorably with
thoseof a recentlypublishedMS/MSmethod inwhich the
limit of quantification was not sufficiently low to allow
quantification of lysoGb3 in healthy individuals (9).
These authors used a glycine derivative of lysoGb3, Gly-
lysoGb3, as an internal standard. The synthesis of this
compound is less complicated than the synthesis of
[5,6,7,8,9] 13C5-labeled internal standard described here.
However, the structure of this compound is closely re-
lated, but not identical to lysoGb3, whichmay affect both
the extraction efficiencies as well as themass spectromet-
ric behavior in different matrices. It should be noted that
the measured absolute amounts of lysoGb3 in plasma of
hemizygous and heterozygous Fabry patients were lower
than previously determined by HPLC measurements
(5, 10, 11). This differencemay be attributed to an impu-
rity of commercial lysoGb3 standardused in these studies
(seeMaterials andMethods).
Fig. 2. LysoGb3 concentrations in plasma of 10 clas-
sically affected Fabry hemizygotes, 10 classically af-
fected Fabry heterozygotes, and 20 controls (semi-
logarithmic plot).
Hemizygote: 94.4 (25.8) pmol/mL, range 52.7–136.8 pmol/
mL. Heterozygote: 9.6 (5.8) pmol/mL, range 4.1–23.5 pmol/
mL. Control: 0.4 (0.1) pmol/mL, range 0.3–0.5 pmol/mL.
MRM, multiple reaction monitoring.
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PRESENCE OF A Lyso-ene-Gb3 IN PLASMA AND URINE FROM
FABRY PATIENTS
Wehave previously shown that, in addition to lysoGb3,
a related compound with higher polarity accumulates
in patients with Fabry disease (5 ). This compound was
tentatively identified byAuray-Blais and coworkers as a
lyso-ene-Gb3 (8 ). Prompted by this finding, we mon-
itored the transition 784.4  280.3 in addition to the
transitions 786.4 282.3 (lysoGb3) and 791.4 287.3
([5,6,7,8,9] 13C5-labeled lysoGb3). A peakwith a reten-
tion time slightly shorter than the retention times of
lysoGb3 (Fig. 4A) and that of labeled lysoGb3 (Fig. 4B)
was found in plasma (Fig. 4C) and urine of male Fabry
patients (urine not shown). These data suggest that
compound X is indeed a lysoGb3 with a sphingosine
base containing 1 additional double bond, consistent
with the findings of Auray-Blais and colleagues (8 ).
Although we did not establish the position of the dou-
ble bond, the most likely position is that of a 4E, 14Z-
sphingadiene (4E, 14Z-18:2-sphingosine) (15). The
fragmentation spectrum of the peak of the chromato-
gram fits with lyso-ene-Gb3 (see online Supplemental
Fig. 2). The fragmentation spectrumof lyso-ene-Gb3 is
highly comparable to that of lysoGb3, allowing the
quantification of lyso-ene-Gb3 with ( [5,6,7,8,9] 13C5-
labeled lysoGb3 as the internal standard.
QUANTIFICATION OF LysoGb3 AND Lyso-ene-Gb3 IN PLASMA AND
URINE FROM FABRY PATIENTS
The concentrations of lysoGb3 and lyso-ene-Gb3 were
determined in plasma and urine of 9male patients with
classical Fabry disease fromwhomaplasma sample and
a 24-h urine sample were collected at the same time
before treatment. The results for lysoGb3 in plasma are
shown in Fig. 4D and are comparable to those in Fig. 1.
Lyso-ene-Gb3 was found to be increased in all exam-
ined plasma samples, but the concentrations were con-
Fig. 3. Elution profile of plasma lysoGb3 for a healthy individual.
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Fig. 4. Detection of lyso-ene-Gb3 in plasma.
(A), Elution profile of lysoGb3; (B), elution profile of [5,6,7,8,9] 13C5-lysoGb3; (C), elution profile of lyso-ene-Gb3; (D),
quantification of lyso-ene-Gb3 in plasma and urine from Fabry patients: comparison with lysoGb3.
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sistently lower than those of lysoGb3 (10%–25% of to-
tal lysoGb3) (Fig. 4D).
For the determination of lysoGb3 and lyso-ene-
Gb3 in urine, 400 L of urine was extracted as de-
scribed in Materials and Methods. The second sample
clean-up step by butanol extraction was necessary to
obtain sufficiently clean analyte preparations. A cali-
bration curve of lysoGb3 in control urine was con-
structed. Control urine from a healthy individual was
supplemented with lysoGb3 in concentrations ranging
from 0–25–50–100–250–500–1000–2500–5000 fmol/
mL, internal standard (1000 fmol/mL) was added, and
the samples were extracted. No lysoGb3 could be de-
tected in normal urine. The ratio of the area of ly-
soGb3/area of [5,6,7,8,9] 13C5-labeled internal stan-
dard was plotted against the concentration of the
lysoGb3 standard. A linear response was obtained over
the entire concentration range (y  0.00122x, R2 
0.998). The limit of detection, defined as a signal-to-
noise ratio of 3, was 15 fmol/mL; the limit of quantifi-
cation, defined as signal-to-noise ratio of 10, was 50
fmol/mL. Thus, the detection capability of the method
for the determination of lysoGb3 in urine was compa-
rable to that for plasma (see above). The intraassay CV
for this assay was 11.2% for a urine sample with a low
concentration of lysoGb3 [97.2 (10.9) fmol/mL, n
10] and 5.3% for a urine sample with a high concen-
tration of lysoGb3 [1106 (58) fmol/mL, n 10]. The
interassay CV was 7.7% for the urine sample with a
low concentration [95.0 (7.3) fmol/mL, n 10] and
9.5% for the sample with a high concentration of
lysoGb3 [1186 (112) fmol/mL, n  10]. The repro-
ducibility of the retention times was comparable to
that in plasma [3.14 (0.01) min for lysoGb3, n 10].
Carryover was determined by processing a urine
sample with a highest concentration of lysoGb3 of
the calibration curve (5000 fmol/mL). No carryover
was observed.
The concentrations of lysoGb3 and lyso-ene-Gb3
expressed per millimole creatinine are shown in Fig.
4D. Creatinine in urine was measured by the Jaffe re-
action on the Cobas P800 (Roche Diagnostics) (16).
Both lysoGb3 and lyso-ene-Gb3 were detectable in all
urine samples from classical Fabry patients, but not in
samples fromhealthy individuals. In urine, the concen-
trations of lyso-ene-Gb3 were comparable to or even
higher than those of lysoGb3 (30%–80% of total
lysoGb3, Fig. 4D). In contrast, the concentrations of
lyso-ene-Gb3 in plasma were consistently lower than
those of lysoGb3. The concentrations of lysoGb3 in
plasma were in the nanomolar range, and the concen-
trations in urine were in the picomolar range, in agree-
ment with earlier findings (8 ). This means that
lysoGb3 and lyso-ene-Gb3 are likely reabsorbed by the
kidney and barely excreted in the urine. The total uri-
nary excretion per 24 h in these 9 patients varied from
0.3 to 3.8 nmol/24 h. for lysoGb3 and from 0.8 to 3.0
nmol/24 h. for lyso-ene-Gb3. The use of 24-h urine
collections allowed us to determine the daily excretion
of lysoGb3 and lyso-ene-Gb3. In principle, random
urine samples could also be used for the quantification
of lysoGb3 and lyso-ene-Gb3 in urine. In our view,
plasma is the preferred material for diagnostic pur-
poses and follow-up of treatment of patients with
Fabry disease given that the concentrations of lysoGb3
and lyso-ene-Gb3 in plasma are 2–3 orders of magni-
tude higher than in urine. In addition, the plasma com-
partment is likely to be more representative of the tis-
sue content of lysoGb3 than urine.
Conclusions
Our UPLC-ESI-MS/MS method takes advantage of an
isotope-labeled internal standard with a chemical
structure identical to the analyte. Variations in recov-
ery during the extraction procedures are corrected for
and matrix effects are minimized. The assay is robust,
sensitive, accurate, and reproducible. All classically af-
fected hemizygote Fabry patients and all heterozygous
Fabry females with relatives with classic disease mani-
festation examined so far showed abnormally high
plasma concentrations of lysoGb3. Thus, next to mu-
tation analysis, the method is a very useful diagnostic
tool to identify female carriers of classic Fabry disease.
Because the method allows accurate quantification of
lysoGb3 in plasma of healthy individuals, it should be
particularly useful in the analysis of lysoGb3 concen-
trations in plasma of patients with an atypical clinical
presentation of Fabry disease, who might present with
lysoGb3 concentrations within reference intervals or
only slightly increased (9 ). The concentrations of ly-
soGb3 and lyso-ene-Gb3 in the urine of male hemizy-
gotes with the classic presentation of Fabry disease are
40–480-fold lower than in plasma, and for urine a
more elaborate sample clean-up is required. For diag-
nostic purposes, we recommend the determination of
lysoGb3 in plasma.
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